- Home
- CNXN vs ADPT Comparison
CNXN vs ADPT Comparison
Compare CNXN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNXN
- ADPT
- Stock Information
- Founded
- CNXN 1982
- ADPT 2009
- Country
- CNXN United States
- ADPT United States
- Employees
- CNXN N/A
- ADPT N/A
- Industry
- CNXN Catalog/Specialty Distribution
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNXN Consumer Discretionary
- ADPT Health Care
- Exchange
- CNXN Nasdaq
- ADPT Nasdaq
- Market Cap
- CNXN 1.7B
- ADPT 1.4B
- IPO Year
- CNXN 1998
- ADPT 2019
- Fundamental
- Price
- CNXN $67.28
- ADPT $11.80
- Analyst Decision
- CNXN
- ADPT Strong Buy
- Analyst Count
- CNXN 0
- ADPT 7
- Target Price
- CNXN N/A
- ADPT $10.57
- AVG Volume (30 Days)
- CNXN 102.9K
- ADPT 2.2M
- Earning Date
- CNXN 07-30-2025
- ADPT 07-31-2025
- Dividend Yield
- CNXN 0.89%
- ADPT N/A
- EPS Growth
- CNXN 6.26
- ADPT N/A
- EPS
- CNXN 3.30
- ADPT N/A
- Revenue
- CNXN $2,871,139,000.00
- ADPT $189,527,000.00
- Revenue This Year
- CNXN $9.74
- ADPT $24.46
- Revenue Next Year
- CNXN $4.75
- ADPT $20.25
- P/E Ratio
- CNXN $20.37
- ADPT N/A
- Revenue Growth
- CNXN 4.21
- ADPT 8.61
- 52 Week Low
- CNXN $56.82
- ADPT $3.30
- 52 Week High
- CNXN $77.19
- ADPT $12.43
- Technical
- Relative Strength Index (RSI)
- CNXN 59.43
- ADPT 66.39
- Support Level
- CNXN $65.33
- ADPT $11.17
- Resistance Level
- CNXN $67.78
- ADPT $12.43
- Average True Range (ATR)
- CNXN 1.30
- ADPT 0.60
- MACD
- CNXN 0.26
- ADPT 0.03
- Stochastic Oscillator
- CNXN 88.03
- ADPT 75.10
About CNXN PC Connection Inc.
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).